Low dose pegylated recombinant human granulocyte colony-stimulating factor in the prophylactic treatment of grade Ⅲ/Ⅳ myelosuppression after chemotherapy
Journal Title: Chinese Journal of Clinical Research - Year 2024, Vol 37, Issue 10
Abstract
"Objective To investigate the impact of low-dose pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) on grade Ⅲ/Ⅳ myelosuppression following chemotherapy. Methods A total of 80 patients with malignant tumors admitted to the First Affiliated Hospital of Anhui University of Science and Technology from April 2022 to September 2023 were selected as research subjects. The patients were randomly divided into the control group (n=40) and the observation group (n=40). The observation group and the control group received subcutaneous injections of 3.0 mg and 6.0 mg PEG-rhG-CSF, respectively, within 24 to 48 hours after chemotherapy. The incidence and duration of grade Ⅲ/Ⅳ neutropenia, febrile neutropenia (FN), adverse reactions, as well as changes in quality of life ［European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)］ scores before and after treatment were observed in both groups after medication. Results After medication, there was no significant difference in the incidence of grade Ⅲ/Ⅳ neutropenia or FN between the two groups (P＞0.05). The observation group exhibited higher levels for neutrophils compared to control group ［(1.77±0.70)×109/L vs (1.50±0.41)×109/L, t=2.071, P=0.042］. Grade Ⅲ/Ⅳ neutropenia occurred in 1 case in the control group, which lasted for 1 day, while 3 cases occurred in the observation group, which lasted for 2-4 days. Compared with the control group, the occurrence rate of adverse reactions was lower in the observation group (72.50% vs 90.00%, χ<sup>2</sup>=4.021, P=0.045), and EORTC QLQ-C30 were higher for patients in the observation group (P＜0.05). Conclusion Low-dose PEG-rhG-CSF demonstrates similar efficacy rates as standard doses for prophylactic managing gradeⅢ/Ⅳ myelosuppression following chemotherapy, but it exhibits a lower incidence rate of adverse reactions and improves quality-of-life of patients."
Authors and Affiliations
WANG Jin, TIE Xiaowei, FU Baobao, JIA Qianqian, WANG Fang, LI Wei
Keywords
Related Articles
- EP ID EP749061
- DOI -
- Views 51
- Downloads 0
Clinical analysis and treatment of superficial vein thrombophlebitis of lower extremities
Objective： To investigate the etiologies, clinical features, and treatment outcomes of patients with superficial vein thrombophlebitis (SVT) respectively. Methods： The clinical data of 67 patients with acute SVT of...
Research progress on the pathogenesis and treatment of cervical spondylotic myelopathy
Cervical spondylotic myelopathy (CSM) is the most serious subtype of cervical spondylosis, which is the main cause of spinal cord dysfunction in middle-aged and elderly people, and the pathogenesis of this CSM is complex...
Genetic causes of isolated congenital heart disease
The genetic mechanism of congenital heart disease (CHD) is complex and currently lacks a clear understanding. Literature studies on CHD often report the presence of concurrent extracardiac anomalies, but since the majori...
Diagnostic value of serum soluble suppression of tumorigenicity 2 in patients with heart failure in different types of heart diseases
Objective To observe the changes of soluble growth stimulation expression gene 2 (sST2) level in patients with heart failure in different types of heart diseases, and analyze the diagnostic value of sST2 in heart failur...
Mechanism and treatment progress of disseminated intravascular coagulation in sepsis
Sepsis is the main cause of death in critically ill patients in clinic, with high incidence and complicated pathogenesis. Coagulation system is an important factor of the pathogenesis and lethal mechanism of sepsis, espe...